Patients preference in the treatment of erectile dysfunction: A critical review of the literature

International Journal of Impotence Research

Volumn 23, Issue 1, 2011, Pages 1-8

  Morales, A Martin ^a   Casillas, M ^b   Turbi, C ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b ELI LILLY AND COMPANY   (Spain)

Author keywords

Erectile dysfunction; preference; sildenafil; tadalafil; vardenafil

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ERECTILE DYSFUNCTION; HUMAN; PATIENT AUTONOMY; PATIENT PREFERENCE; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; UNSPECIFIED SIDE EFFECT;

ERECTILE DYSFUNCTION; HUMANS; MALE; PATIENT PREFERENCE; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 79951960763     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2010.29     Document Type: Review

References (41)

1. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes an (Pubitemid 40299993)
2. Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E et al. Epidemiology/risk factors of sexual dysfunctions. J Sex Med 2004; 1: 35-39.
3. Hedelin H, Ströberg P. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. Drugs 2005; 65: 2245-2251. (Pubitemid 41571984)
4. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int 2009; 103: 1212-1217.
5. Bai WJ. Tadalafil for erectile dysfunction: excellent safety and tolerance. Zhonghua Nan Ke Xue 2009; 15: 92-95.
6. Zhang K, Zhu JC. A decade's evidence review of sildenafil citrate. Zhonghua Nan Ke Xue 2009; 15: 3-6.
7. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009; 6: 2352-2364.
8. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55: 334-347.
9. Eardley I, Lee JC, Guay AT. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Int J Clin Pract 2008; 62: 1594-1603.
10. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, doubleblind, placebo-controlled trial. J Androl 2002; 23: 763-771. (Pubitemid 36300965)
11. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-1336. (Pubitemid 35034115)
12. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404. (Pubitemid 28221980)
13. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61: 280-288. (Pubitemid 43382627)
14. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects, and dose proportionality. Br J Clin Pharmacol 2002; 53: S5-S12.
15. Stark S, Sachse R, Liedl T, Hensen J, Rohde G,Wensing G et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-188.
16. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T et al. The 'effectiveness' scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 2004; 16: 207-213. (Pubitemid 38858950)
17. Weinstein JN. The missing piece: embracing shared decision making to reform health care. Spine (Phila Pa 1976) 2000; 25: 1-4. (Pubitemid 30035974)
18. Kaplan RM. Shared medical decision-making: a new paradigm for behavioral medicine-1997 presidential address. Ann Behav Med 1999; 21: 3-11. (Pubitemid 29319300)
19. Blumenthal D. Part 1: quality of care-what is it? N Engl J Med 1996; 335: 891-894.
20. Katz JN. Patient preferences and health disparities. JAMA 2001; 286: 1506-1509. (Pubitemid 33015509)
21. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006; 49: 30-37. (Pubitemid 41789951)
22. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004; 14: 367-373. (Pubitemid 39506931)
23. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-2723. (Pubitemid 37510585)
24. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-507. (Pubitemid 38376216)
25. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-1332. (Pubitemid 41743933)
26. Ströberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724-2737. (Pubitemid 37510586)
27. Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, Min KS et al. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J Androl 2007; 9: 760-770. (Pubitemid 350090498)
28. Lee J, Pommerville P, Brock G, Gagnon R, Mehta P, Krisdaphongs M et al. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of erectile dysfunction' observational study. BJU Int 2006; 98: 623-629. (Pubitemid 44185889)
29. Tolrà JR, Campaña JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901-909. (Pubitemid 44269546)
30. Ströberg P, Hedelin H, Ljunggren C. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction-a realistic and feasible option in everyday clinical practice- outcomes of a simple treatment regime. Eur Urol 2006; 49: 900-907.
31. Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J et al. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007; 61: 1850-1862. (Pubitemid 47573096)
32. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-1547. (Pubitemid 29117337)
33. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271-1275. (Pubitemid 38823951)
34. Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, openlabel, crossover study. BJU Int 2007; 100: 122-129. (Pubitemid 46878565)
35. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JC, Saoud JC, Ferguson KM et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2-9. (Pubitemid 32274643)
36. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199. (Pubitemid 32743600)
37. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993; 270: 83-90.
38. Althof SE, Eid JF, Talley DR, Brock GB, Dunn ME, Tomlin ME et al. Through the eyes of women: the partners' perspective on tadalafil. Urology 2006; 68: 631-635. (Pubitemid 44436502)
39. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005; 2: 675-684. (Pubitemid 41742928)
40. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. J Sex Med 2008; 5: 1198-1207. (Pubitemid 351606705)
41. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase- 5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43: 260-267. (Pubitemid 36232654)